Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what discussions he has had with the Royal Colleges on the cancer drug known as anti-PDL1; and when he expects that drug to be available for use in the NHS.

There have been no discussions with the Royal Colleges on the use of anti- PDL1 to treat cancer. In order for a medicine to be placed on the United Kingdom and European Union markets, the manufacturer must first apply to obtain a Marketing Authorisation from either the European Medicines Agency or the Medicines and Healthcare products Regulatory Agency. This medicine appears to be in early stage development and no estimation can be made of when it will be placed on the market.